Olema Oncology
Gopinath Palanisamy joined Olema in November 2020 and serves as Vice President of Pre-Clinical Pharmacology and Toxicology. Dr. Palanisamy has extensive, broad-based non-clinical drug development experience in the pharmaceutical/biotechnology industry and academia as a scientist, toxicologist and an American board-certified veterinary pathologist. He has held positions of increasing responsibility in his previous roles at Theravance Biopharma, Genentech, and Pfizer leading drug discovery project teams and non-clinical development teams. He has interacted frequently with global regulatory authorities and co-authored multiple regulatory documents. Dr. Palanisamy received his veterinary pathology residency training and Ph.D. in microbiology/pathology from Colorado State University, an M.S. in reproductive endocrinology from University of Illinois at Urbana-Champaign and a doctorate in veterinary medicine from Tamilnadu Veterinary and Animal Sciences University, India.
Olema Oncology
Olema Oncology is a biopharmaceutical company developing innovative targeted therapies for women’s cancers. Their lead program, OP-1250, a potential best-in-class complete estrogen receptor antagonist (CERAN), is in development to treat estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema recently initiated a Phase 1/2 dose-escalation and expansion clinical trial of OP-1250. They are supported in their mission by experienced and accomplished scientists and board members, leading healthcare investors and some of the most innovative pharma companies.